Results 191 to 200 of about 259,795 (258)

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo   +38 more
wiley   +1 more source

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options.
Ioannis Ntanasis‐Stathopoulos   +7 more
wiley   +1 more source

A Novel Plasma Heme Assay Reveals Disease Severity in Beta‐Thalassemia and Sickle Cell Anemia

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Anemia results from imbalanced hemoglobin or red blood cell production and clearance. Hemolytic anemia, caused by premature red blood cell removal, can be intravascular (in blood) or extravascular (erythrophagocytosis). Hemolysis is common in Sickle Cell Disease (SCD) and Beta‐Thalassemia anemia (β‐thalassemia), the most prevalent inherited ...
Laurent Kiger   +14 more
wiley   +1 more source

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights

open access: yesAmerican Journal of Hematology, EarlyView.
CTC offer a minimally invasive widow into systemic myeloma biology, overcoming the sampling bias of bone marrow biopsies. Their prognostic value at diagnosis, potential role in MRD monitoring, and ability to capture clonal evolution highlight them as actionable biomarkers for future precision medicine.
Benjamin Podvin   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy